Learn more about whether Ionis Pharmaceuticals, Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30th at 11:30 ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today and set a price target of $59.00.

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with ...

CARLSBAD, Calif., April 03, 2025--Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today it will host a webinar on Monday, April 14th at 11:00 a.m. ET focused on the risks, clinical ...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Regulus Therapeutics Inc.’s RGLS share price has surged by 5.41%, which has investors questioning if this is right time to sell.

GS. Sony increases costs of PS5 in Europe, Australia, and New Zealand amid tariff risks. Tech stocks rebound on Trump tariff ...